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ABO blood group is a predictor 
of survival in patients with laryngeal cancer
Ting Jin1,2†, Pei‑Jing Li3†, Xiao‑Zhong Chen1,2* and Wei‑Han Hu3*
Abstract 
Background: Whether the ABO blood group is associated with the survival of patients with laryngeal cancer remains 
unknown. The purpose of this study was to investigate the association between the ABO blood group and clinico‑
pathologic characteristics of patients with laryngeal cancer and assess whether the ABO blood group was associated 
with prognosis.
Methods: We analyzed the records of 1260 patients with laryngeal cancer who underwent curative treatment at Sun 
Yat‑sen University Cancer Center between January 1993 and December 2009. The Chi‑square test was used to assess 
the relationship between the ABO blood group and clinicopathologic characteristics. The Kaplan–Meier method 
was used to estimate 3‑, 5‑, and 10‑year overall survival (OS) rates. The Cox proportional hazards model was used in 
univariate and multivariate analyses of OS.
Results: No significant association was found between the ABO blood group and clinicopathologic characteristics 
except for primary tumor site. The median OS for patients with blood groups A, B, AB, and O were 87.0, 80.0, 90.0, and 
72.5 months, respectively. The 3‑, 5‑, and 10‑year OS rates were 82.4%, 76.0%, and 67.5% for patients with blood group 
A; 77.4%, 69.8%, and 58.4% for patients with blood group B; 82.2%, 73.1%, and 65.6% for patients with blood group 
AB; and 71.7%, 66.4%, and 55.5% for patients with blood group O, respectively. Univariate and multivariate analyses 
showed that the ABO blood group had significant effects on prognosis in patients with laryngeal cancer.
Conclusions: The ABO blood group is associated with survival in patients with laryngeal cancer. Patients with blood 
group O had significantly shorter OS than patients with other ABO blood groups.
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Background
In the United States, it is estimated that approximately 
53,640 new cases of oral cavity, pharyngeal, and laryn-
geal cancers were diagnosed in 2013. During the same 
period, an estimated 11,520 deaths from head and neck 
cancers occurred [1]. Approximately 20% of head and 
neck tumors originate in the larynx [1]. Laryngeal cancer 
can be largely prevented by controlling behavioral risk 
factors, such as alcohol consumption and cigarette smok-
ing. Human papillomavirus infection was also found to 
be significantly associated with the risk of laryngeal can-
cer [2]. Importantly, some patients without strong risk 
factors present with particularly aggressive laryngeal car-
cinoma. Such cases mandate the investigation of other 
possible predisposing factors, such as the ABO blood 
group [3].
Several previous studies, which, taken together, 
included a relatively small number of patients, exam-
ined the relationship between the ABO blood group and 
the incidence of laryngeal cancer. In 1992, in a study of 
people living in southern Poland, Konieczna et  al. [4] 
found that the blood group A2B was present significantly 
more frequently in 153 patients with epiglottic can-
cer compared with 22,422 healthy individuals; however, 
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the difference was not significant with respect to 3- and 
5-year survival rates. In 1995, in another study of peo-
ple living in Poland, Pyd et al. [5] reported that the blood 
group A2 was present significantly more frequently in 
a group of patients with glottic cancer compared with 
supraglottic and subglottic cancer and that the blood 
group A1B was present significantly more frequently in a 
group of patients with hypopharyngeal cancer compared 
with laryngeal caner. Conversely, in 2000, Nowinska et al. 
[6] retrospectively studied yet another population living 
in southern Poland and found that differences among 
distinct ABO blood groups were not significant between 
205 laryngeal cancer patients and 5168 healthy individu-
als. Few studies have examined the effect of the ABO 
blood group on the survival of patients with laryngeal 
cancer. Adam et al. [3] reported no association between 
the ABO blood group and 5 year survival and mortality 
in 143 laryngeal cancer patients.
Whether the ABO blood group is associated with 
the survival of patients with laryngeal cancer remains 
unknown. Therefore, we retrospectively studied a con-
secutive cohort of patients in China who presented with 
locoregional laryngeal cancer and underwent curative 
treatment. The purpose of this study was to elucidate 
the association between the ABO blood group and the 
clinicopathologic characteristics of patients with laryn-
geal cancer and determine whether a specific ABO blood 
group is an independent predictor of prognosis.
Methods
Ethics, consent, and permissions
This study was approved by the Human Ethics Approval 
Committee at Sun Yat-sen University Cancer Center 
(registration number: B2011-06-15); requirement to 
obtain informed consent was waived.
Patients
We reviewed the records of patients treated at Sun Yat-
sen University Cancer Center between January 1993 and 
December 2009 and found 1477 patients with primary 
squamous cell carcinoma of the larynx. The patient selec-
tion criteria were as follows: (1) each patient had com-
plete clinicopathologic data, including age, sex, stage, 
smoking index, alcohol consumption, histologic differen-
tiation, the ABO blood group, and treatment status; (2) 
diseases were restaged according to the 2002 Union for 
International Cancer Control (UICC) cancer staging sys-
tem, and no patient had distant metastasis at the time of 
initial staging; and (3) patients were initially treated with 
curative intent by one or a combination of surgery, radia-
tion therapy, and chemotherapy. The ABO blood group 
(A, B, O, or AB) was determined using mouse-derived 
monoclonal antibodies (Ortho Bioclones Anti-A, B, and 
O; Ortho Diagnostic Systems Inc., Raritan, NJ, USA). 
After cessation of treatment, each patient was followed 
up every 3 months at the clinic or by telephone contact 
for an interview. The last follow-up was December 31, 
2013.
Treatment
Surgical methods included total laryngectomy, partial 
laryngectomy, and chordectomy for primary tumors. In 
the surgical treatment of the neck, modified radical neck 
dissection (MRND) and selective neck dissection (SND) 
were used. Cisplatin-based regimen was used for neoad-
juvant chemotherapy, adjuvant chemotherapy, and con-
current chemoradiotherapy. Radiotherapy was delivered 
employing 60Co units or 6-MV linear accelerator. Total 
radiation dose in the area of clinical target volume ranged 
from 50 to 82 Gy (median, 60 Gy).
Statistical analyses
Overall survival (OS) was calculated from the date of 
diagnosis to the date of death or the last follow-up. The 
relationship between the ABO blood group and clin-
icopathologic variables was assessed by the Chi-square 
test. For univariate analysis, OS was estimated using the 
Kaplan–Meier method, and the statistical significance 
of differences between curves was tested using the log-
rank test. To determine independent prognostic factors, 
variables found to have a significant association with OS 
(P < 0.05) on univariate analyses were included in the mul-
tivariate models. P values less than 0.05 were considered 
statistically significant. All statistical analyses were per-
formed using the Statistical Package for the Social Sciences 
software (SPSS version 21.0; SPSS Inc., Chicago, IL, USA).
Results
Overall study population
Baseline clinicopathologic characteristics of the whole 
study population are listed in Table  1. In total, 1260 
patients were identified for our study; of these, 1226 
were men, and 34 were women. For the whole cohort of 
patients, the median age at diagnosis was 61 years (range, 
22–93 years). A total of 747 patients had UICC stage I–
II disease, and 513 had UICC stage III–IV disease. Eight 
hundred eighty-five patients had glottic cancer, 331 had 
supraglottic cancer, and 44 had subglottic cancer. Addi-
tionally, 808 patients had never consumed alcohol, 
whereas 452 patients had. Three hundred forty-seven 
patients (27.5%) had blood group A, 332 had blood group 
B (26.4%), 101 had blood group AB (8.0%), and 480 had 
blood group O (38.1%). No significant association was 
found between the ABO blood group and sex, age, smok-
ing index, alcohol consumption, tumor differentiation, T 
category, N category, and UICC TNM stage (Table 1).
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Of the 1260 patients identified, 795 underwent radi-
cal resection alone, 68 received definitive radiation alone, 
14 received definitive concurrent chemoradiotherapy, 
298 underwent surgery plus postoperative radiotherapy, 
23 underwent surgery plus adjuvant chemotherapy, 11 
underwent surgery plus adjuvant concurrent chemoradio-
therapy, 7 received radiotherapy before surgery, 4 received 
neoadjuvant chemotherapy plus surgery, 24 received 
neoadjuvant chemotherapy plus definitive concurrent 
chemoradiotherapy, 1 received concurrent chemoradio-
therapy before surgery, 5 underwent surgery plus postoper-
ative radiotherapy and adjuvant chemotherapy, 6 received 
neoadjuvant chemotherapy plus surgery and postoperative 
radiotherapy, 1 received neoadjuvant chemotherapy plus 
surgery and adjuvant chemotherapy, 2 received neoadju-
vant chemotherapy plus surgery and adjuvant concurrent 
chemoradiotherapy, and 1 received neoadjuvant chemo-
therapy plus concurrent chemoradiotherapy and surgery.
Table 1 Baseline characteristics of 1260 laryngeal cancer patients divided by different ABO blood groups
UICC Union for International Cancer Control
a Patients were divided into two groups according to the median age
b Smoking index was defined as the number of cigarettes smoked per day × the total smoking duration (years)
Characteristic Total ABO blood group [cases (%)] χ2 P
A (n = 347) B (n = 332) AB (n = 101) O (n = 480)
Sex 1.576 0.665
 Men 1226 338 (27.6) 320 (26.1) 99 (8.1) 469 (38.2)
 Women 34 9 (26.5) 12 (35.3) 2 (5.9) 11 (32.3)
Age (years)a 2.122 0.547
 ≤61 661 176 (26.6) 168 (25.4) 53 (8.0) 264 (40.0)
 >61 599 171 (28.5) 164 (27.4) 48 (8.0) 216 (36.1)
Smoking indexb 4.010 0.260
 ≤600 659 191 (29.0) 178 (27.0) 45 (6.8) 245 (37.2)
 >600 601 156 (26.0) 154 (25.6) 56 (9.3) 235 (39.1)
Alcohol consumption 4.899 0.179
 No 808 219 (27.1) 226 (28.0) 69 (8.5) 294 (36.4)
 Yes 452 128 (28.3) 106 (23.5) 32 (7.1) 186 (41.1)
Tumor differentiation 3.452 0.750
 Well 600 170 (28.4) 149 (24.8) 54 (9.0) 227 (37.8)
 Moderate 481 132 (27.4) 134 (27.9) 32 (6.7) 183 (38.0)
 Poor 179 45 (25.1) 49 (27.4) 15 (8.4) 70 (39.1)
Primary site 16.755 0.010
 Glottic 885 244 (27.6) 242 (27.3) 79 (8.9) 320 (36.2)
 Supraglottic 331 83 (25.1) 82 (24.8) 22 (6.6) 144 (43.5)
 Subglottic 44 20 (45.5) 8 (18.2) 0 (0) 16 (36.3)
T category 7.212 0.615
 T1 434 119 (27.4) 123 (28.4) 31 (7.1) 161 (37.1)
 T2 382 115 (30.1) 94 (24.6) 31 (8.1) 142 (37.2)
 T3 244 58 (23.8) 65 (26.6) 26 (10.7) 95 (38.9)
 T4 200 55 (27.5) 50 (25.0) 13 (6.5) 82 (41.0)
N category 2.319 0.509
 N0 1021 289 (28.3) 269 (26.3) 83 (8.1) 380 (37.2)
 N+ 239 58 (24.3) 63 (26.4) 18 (7.5) 100 (41.8)
UICC stage 9.077 0.430
 I 421 118 (28.0) 118 (28.0) 29 (6.9) 156 (37.1)
 II 326 101 (31.0) 77 (23.6) 27 (8.3) 121 (37.1)
 III 242 54 (22.3) 66 (27.3) 26 (10.7) 96 (39.7)
 IV 271 74 (27.3) 71 (26.2) 19 (7.0) 107 (39.5)
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Survival analyses by the ABO blood group
For the entire patient group, the median OS was 
80 months; the 3-, 5-, and 10-year OS rates were 77.5%, 
70.5%, and 60.4%, respectively. The 3-, 5-, and 10-year 
OS rates were 82.4%, 76.0%, and 67.5% for patients 
with blood group A; 77.4%, 69.8%, and 58.4% for 
patients with blood group B; 82.2%, 73.1%, and 65.6% 
for patients with blood group AB; and 71.7%, 66.4%, 
and 55.5% for patients with blood group O, respec-
tively. The median OS for patients with blood groups 
A, B, AB, and O was 87.0, 80.0, 90.0, and 72.5 months, 
respectively. We found a significant difference in OS 
between different ABO blood groups (P  =  0.009; 
Fig. 1). Furthermore, for the entire cohort, we analyzed 
the association of the ABO blood group with OS rates. 
For patients with laryngeal cancer, univariate analyses 
indicated a significant association between OS rates 
and sex, age, smoking index, alcohol consumption, 
tumor differentiation, the ABO blood group, primary 
tumor site, T category, N category, and UICC TNM 
stage (Table 2). 
Multivariate analysis showed that age, alcohol con-
sumption, tumor differentiation, the ABO blood group, 
T category, and N category were independent prognostic 
factors (Table 3).
Discussion
In our study of 1260 patients with laryngeal cancer, we 
investigated the association between the ABO blood 
Fig. 1 Overall survival curves for 1260 laryngeal cancer patients 
stratified by the ABO blood group. The 3‑, 5‑, and 10‑year OS rates 
were 82.4%, 76.0%, and 67.5% for patients with blood group A; 77.4%, 
69.8%, and 58.4% for patients with blood group B; 82.2%, 73.1%, and 
65.6% for patients with blood group AB; and 71.7%, 66.4%, and 55.5% 
for patients with blood group O, respectively (P = 0.009)
Table 2 Univariate prognostic analysis for overall survival 
(OS) rates of 1260 patients with laryngeal cancer
UICC Union for International Cancer Control
a Patients were divided into two groups according to the median age
b Smoking index was defined as the number of cigarettes smoked per day × the 
total smoking duration (years)
Variable No. of  
patients
OS rate (%) χ2 P
5-year 10-year
Sex 6.079 0.014
 Men 1226 70.0 59.7
 Women 34 85.3 85.3
Age (years)a 35.892 <0.001
 ≤61 661 76.0 68.7
 >61 599 64.4 51.5
Smoking indexb 8.322 0.004
 ≤600 659 73.2 64.1




 No 808 72.3 62.5
 Yes 452 67.2 56.6
Differentiation 27.775 <0.001
 Well 600 76.8 65.7
 Moderate 481 68.5 58.4
 Poor 179 54.6 48.1
Primary site 31.102 <0.001
 Glottic 885 74.8 64.8
 Supraglottic 331 58.6 48.7
 Subglottic 44 72.7 56.2
Blood group 11.637 0.009
 A 347 76.0 67.5
 B 332 69.8 58.4
 AB 101 73.1 65.6
 O 480 66.4 55.5
T category 101.754 <0.001
 T1 434 84.2 72.0
 T2 382 74.3 63.0
 T3 244 59.4 51.4
 T4 200 46.8 41.1
N category 119.722 <0.001
 N0 1021 76.9 66.1
 N+ 239 43.0 35.4
UICC stage 127.473 <0.001
 I 421 85.4 73.5
 II 326 77.2 65.3
 III 242 62.4 52.6
 IV 271 46.3 41.4
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group and clinicopathologic characteristics and patient 
prognosis. We found no significant association between 
clinicopathologic characteristics and the ABO blood 
group. Univariate and multivariate analyses showed that 
the ABO blood group was significantly associated with 
the prognosis of patients with laryngeal cancer.
There are more than 100 recognized blood group sys-
tems composed of more than 500 antigens [7], of which 
the ABO blood group is considered the most important 
[8]. The ABO blood group is determined by the pres-
ence of A or B blood group antigens on the surface of red 
blood cells, which consist of proteins and carbohydrates 
attached to lipids or proteins. Red blood cell antigens 
have various functions, such as membrane structural 
integrity, transportation of molecules through mem-
branes, and adhesion [9]. Along with their expression 
on red blood cells, ABO antigens are highly expressed 
on human tissues and most epithelial and endothelial 
cells [10, 11]. Since the first report by Aird et  al. [12] 
that showed an association between blood group A and 
gastric cancer, the relationship between the ABO blood 
group and the risk, incidence, and clinicopathologic 
characteristics of human tumors has been suspected. 
Moreover, many studies have suggested a possible rela-
tionship between ABO blood group antigens and pro-
gression of human tumors [13–18]. Several plausible 
mechanisms, such as inflammation, immune-surveillance 
of malignant cells, and membrane signaling, have been 
proposed to explain this observed association between 
the ABO blood group and cancer risk [19]. Whereas 
the relationship between the ABO blood group and the 
incidence of laryngeal cancer remains unclear [4–6], the 
association between the ABO blood group and the risk 
of pancreatic cancer has been reported for over 40 years. 
Compared with people with blood group O, people with 
non-O blood groups have an adjusted hazard ratio (HR) 
for pancreatic cancer of 1.44 (95% confidence interval 
[CI] 1.14–1.82) [19]. Many studies have been conducted 
to examine the underlying mechanism of this relation-
ship. For example, the multinational Pancreatic Cancer 
Cohort Consortium identified pancreatic cancer sus-
ceptibility loci in the ABO gene [20]. In this study, 1896 
patients with pancreatic cancer and 1939 controls were 
genotyped, and a significant association was reported 
with rs505922, a single nucleotide polymorphism (SNP) 
that maps to the first intron of the ABO gene. The ABO 
SNP rs505922 is in strong linkage disequilibrium with 
O/non-O blood group alleles, indicating that people 
with non-O blood groups are at increased risk for devel-
oping pancreatic cancer [19, 21, 22]. In addition, two 
recent genome-wide association studies identified vari-
ants in ABO (rs505922), 1q32.1 (rs3790844), 13q22.1 
(rs9543325), and 5p15.3 (rs401681) that were associ-
ated with a modestly increased risk of pancreatic cancer 
[23]. Two other studies suggested that the association 
between A blood group and increased risk of pancre-
atic cancer is due mainly to the A1 allele, thus indicating 
a direct connection between ABO glycosyltransferase 
activity and increased risk of this disease [24, 25]. Risch 
et al. [26] reported that the increased risk of pancreatic 
cancer among people with non-O blood groups was even 
higher if they were also seropositive for CagA-negative 
Helicobacter pylori (odds ratio: 2.78; 95% CI 1.49–5.20). 
Recently, Hofmann et al. [27] reported that healthy con-
trols displayed significantly higher isoagglutinin titers 
and higher rate of binding to Tn and T antigen compared 
with patients with pancreatic ductal adenocarcinoma. 
Because Hofmann et al. [27] did not find an association 
between isoagglutinin titers and clinical parameters (such 
as OS and tumor stage), they assumed that isoagglutinins 
are important during tumorigenesis but not during actual 
tumor growth.
Our study showed, by both univariate and multivariate 
analyses, that the ABO blood group was an independ-
ent prognostic factor for patients with laryngeal cancer. 
Compared with patients with other ABO blood groups, 
patients with blood group O had significantly shorter OS.
There are only a few comparable studies in laryn-
geal cancer or in other types of head and neck cancer. A 
study by Ouyang et  al. [28] indicated that nasopharyn-
geal carcinoma (NPC) patients with blood group A had 
significantly lower OS rate (adjusted HR  =  1.49 [95% 
CI 1.03–2.17]) and distant metastasis-free survival rate 
(HR = 1.68 [95% CI 1.13–2.51]) than patients with non-A 
blood groups (B, AB, and O). In the subgroup analyses, 
they found that the increased risks associated with blood 
group A were restricted to men. Sheng et  al. [17] con-
ducted a case–control study and found that male NPC 
patients with blood group A had a significantly higher 
rate of distant metastasis than male patients with non-A 
Table 3 Multivariate analysis of  OS with  the Cox propor-
tional hazards model
CI confidence interval
Variable Hazard ratio 95% CI P
Alcohol consumption 1.218 1.009–1.470 0.040
Tumor differentiation 1.201 1.057–1.365 0.005
Primary site 0.889 0.738–1.071 0.215
T category 1.334 1.213–1.468 <0.001
ABO blood group 1.101 1.023–1.184 0.010
Sex 0.425 0.175–1.034 0.059
Age 1.877 1.558–2.260 <0.001
Smoking index 1.122 0.934–1.349 0.220
N category 2.203 1.749–2.774 <0.001
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blood groups (6.8% vs. 3.5%, P =  0.027), which directly 
supports the poorer prognosis of men with blood group 
A. A possible reason for the different results between 
laryngeal cancer and NPC is that NPC has a distinct epi-
demiology, etiology, and clinical manifestation compared 
with other head and neck cancers, including laryngeal 
cancer [29, 30].
Our findings are similar to those of previous stud-
ies in non-muscle invasive bladder urothelial carcinoma 
and locoregional esophageal squamous cell carcinoma 
(ESCC). Klatte et  al. [31] found that non-muscle inva-
sive bladder urothelial carcinoma patients with blood 
group O had higher recurrence and progression rates 
than patients with blood group A (P = 0.015 and 0.031, 
respectively) or blood group B (P  =  0.004 and 0.075, 
respectively). In a subgroup analysis of 321 patients with 
ESCC who had ever smoked, Sun et  al. [32] found that 
patients with blood group B/O had lower OS rate than 
patients with blood group A/AB (P = 0.024). For ESCC 
patients who had ever smoked, multivariate analysis 
showed an unfavorable and independent effect of blood 
group B/O on survival (P =  0.011). Our findings, how-
ever, are not in line with the findings of previous studies 
on pancreatic cancer, renal cell carcinoma, and cura-
tively resected non–small cell lung cancer (NSCLC). For 
example, Engin et  al. [33] and Rahbari et  al. [34] found 
that pancreatic cancer patients with blood group O had 
a significantly longer survival than patients with non-O 
blood groups, regardless of prognostic factors. Kaf-
fenberger et  al. [35] showed that, in patients with renal 
cell carcinoma who underwent nephrectomy or par-
tial nephrectomy, non-O blood groups were signifi-
cantly associated with decreased OS (HR = 1.68, 95% CI 
1.18–2.39, P = 0.004). Li et al. [36] showed that NSCLC 
patients with blood group O or B had significantly longer 
OS, disease-free survival, and local recurrence-free sur-
vival than NSCLC patients with blood group A or AB.
The results of studies evaluating the prognostic value of 
the ABO blood group in various cancers are quite con-
flicting. There are several possible explanations for the 
heterogeneity of findings across the studies. First, many 
studies were performed without the understanding that 
ABO frequencies can vary widely in populations assumed 
to be ethnically homogeneous; therefore, they included 
a limited number of patients and inappropriate control 
groups. Second, many studies were retrospective. Third, 
many recent studies that determined the association 
between the ABO blood group and the occurrence of 
malignant neoplastic disease are still preliminary or con-
troversial, frequently not supported by strong statistical 
data. Underlying mechanisms still need to be explored or 
confirmed.
In our study, the distribution of the ABO blood 
group was similar to that in the Zhejiang [17] and 
Guangdong populations [32], with blood group O hav-
ing the highest percentage (38.1%) and blood group AB 
having the lowest percentage (8.0%). It is still unclear 
why ABO blood groups affect the survival of patients 
with laryngeal cancer. Since no significant differences 
in the basic characteristics of patients with differ-
ent ABO blood groups were observed, it is difficult to 
explain the effect of the ABO blood group. However, 
underlying molecular and pathogenic differences may 
play important roles in the effect of the ABO blood 
group on survival.
Our study had several limitations. First, it was con-
ducted at a single center. Second, to detect an association 
between the ABO blood group and survival of patients 
with laryngeal cancer, we selected only the patients with 
locoregional disease that underwent curative treatment. 
Therefore, metastatic cases were excluded and not dis-
cussed. Third, despite the fact that the patients enrolled 
in this study mostly came from Guangdong province, 
some of them came from other areas in China. Fourth, 
worldwide, the general sex ratio (men:women) of laryn-
geal cancer is 8–10:1, but in our study, the ratio was 
36.1:1. These limitations weaken the applicability of our 
data.
In conclusion, this study provides evidence of an associa-
tion between the ABO blood group and survival of patients 
with laryngeal cancer: patients with blood group O had 
lower OS rate than patients with non-O blood groups. Fur-
ther basic research on tumor genetic or biological differ-
ences associated with the ABO blood group is needed.
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